Skip to main content
. 1998 Aug 4;95(16):9642–9647. doi: 10.1073/pnas.95.16.9642

Figure 2.

Figure 2

Therapeutic effect of dEpoB, paclitaxel, and Adriamycin in nude mice bearing the human mammary carcinoma MX-1 xenograft. MX-1 tissue preparation, 100 μl per mouse, was implanted s.c. on day 0. Every other day i.p. treatments were given on days 8, 10, 12, 14, and 16 with 35 mg/kg dEpoB (■), 5 mg/kg paclitaxel (▴), 2 mg/kg Adriamycin (X), and vehicle (DMSO, 30 μl)-treated control (♦). For paclitaxel, 2 of 10 mice died of toxicity on day 18. For Adriamycin, 1 of 10 mice died of toxicity on day 22. For dEpoB, 10 of 10 mice survived and were subjected to the second cycle of treatment at 40 mg/kg on days 18, 20, 22, 24, and 26. This led to 3 of 10 mice tumor-free up to day 80, whereas 7 of 10 mice were with markedly suppressed tumors and were sacrificed on day 50.